| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Fibroblast growth factor-binding protein 3, FGF-BP3, FGF-binding protein 3, FGFBP-3, FGFBP3, C10orf13 |
| Entrez GeneID | 143282 |
| WB Predicted band size | 27.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This FGFBP3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 181-210 amino acids from the C-terminal region of human FGFBP3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4条关于FGFBP3抗体的**模拟参考文献**(仅供示例，具体文献需通过学术数据库检索确认)：
---
1. **文献名称**: *"Monoclonal antibody targeting FGFBP3 inhibits tumor growth and metastasis in colorectal cancer models"*
**作者**: Zhang Y, et al.
**摘要**: 研究开发了一种靶向FGFBP3的单克隆抗体，通过体外和体内实验证明其能有效抑制结直肠癌细胞的增殖和转移，机制可能与阻断FGF信号通路相关。
2. **文献名称**: *"FGFBP3 as a biomarker in hepatocellular carcinoma: Validation of a polyclonal antibody for immunohistochemical detection"*
**作者**: Tanaka K, et al.
**摘要**: 验证了一种多克隆抗体在肝细胞癌组织中的特异性，发现FGFBP3高表达与患者预后不良相关，提示其作为潜在诊断标志物的价值。
3. **文献名称**: *"Neutralizing anti-FGFBP3 antibody attenuates angiogenesis in triple-negative breast cancer"*
**作者**: Gupta R, et al.
**摘要**: 研究利用中和性抗体阻断FGFBP3功能，发现其可显著抑制三阴性乳腺癌的血管生成，为靶向治疗提供了实验依据。
4. **文献名称**: *"Development of a high-affinity FGFBP3 antibody for functional proteomic studies"*
**作者**: Müller S, et al.
**摘要**: 报道了一种高亲和力抗体的开发流程，结合质谱分析揭示了FGFBP3在肿瘤微环境中的相互作用网络，为机制研究提供工具。
---
**注意**：以上内容为模拟示例，实际文献需通过PubMed、Web of Science或Google Scholar等平台检索关键词“FGFBP3 antibody”获取。建议结合具体研究场景筛选近年高质量论文(如Nature、Cell子刊或专业肿瘤学期刊)。
The fibroblast growth factor-binding protein 3 (FGFBP3) is a member of the FGFBP family, which modulates the activity of fibroblast growth factors (FGFs) by binding to and facilitating their interaction with receptors. FGFs play critical roles in tissue repair, angiogenesis, and embryonic development, but dysregulation of FGF signaling is implicated in cancer progression and metastasis. FGFBP3. though less studied than its homolog FGFBP1. is thought to act as a chaperone, stabilizing FGFs or enhancing their bioavailability in the extracellular matrix.
FGFBP3 is overexpressed in certain cancers, including hepatocellular carcinoma and glioblastoma, where it may promote tumor growth, invasion, and resistance to therapy. Its upregulation correlates with poor prognosis, suggesting its potential as a biomarker or therapeutic target. However, the exact molecular mechanisms and regulatory pathways involving FGFBP3 remain under investigation.
Antibodies against FGFBP3 are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They enable techniques like immunohistochemistry, Western blotting, and ELISA to quantify FGFBP3 levels in tissues or serum, aiding in cancer research and diagnostic development. Recent studies also explore therapeutic applications, such as blocking FGFBP3 to inhibit tumor angiogenesis. Despite progress, further validation of antibody specificity and functional assays is needed to fully harness their potential in translational medicine.
×
